Rob focuses on equity capital markets, frequently acting for issuers and banks on IPOs, secondary offerings, takeovers, step-ups and general equity-related transactions.

Rob also regularly advises on M&A transactions, acting for both private and public companies with a particular focus on cross-border transactions, as well as private equity transactions, including MBOs, secondary buyouts, exits and debt/equity reorganisations.

Rob heads up the Life Sciences sector in the Birmingham office.